Outcomes-based risk-sharing schemes: Is there a potential role in the Asia-Pacific markets?

Lisbet Coulton, Lieven Annemans, Rob Carter, Maya Baltazar Herrera, Hasbullah Thabrany, Jeremy Lim, Kenneth K.C. Lee, Wen Chen, Nathorn Chaiyakunapruk, Herng Der Chern, Tae Jin Lee, Hiroshi Nakamura, Tony Yen Huei Tarn, Abdulkadir Keskinaslan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVES: To provide a commentary on outcomes-based risk-sharing schemes in Europe and the US, and to assess characteristics of such schemes and whether they have a potential role in the Asia-Pacific markets. This commentary also examines current experience in the Asia-Pacific markets and considers criteria for such agreements as they might relate to the different health care environments. SUMMARY: Future opportunities for patient access schemes, and specifically, a role for outcomesbased risk-sharing schemes, exist in the Asia-Pacific markets. Four types of agreements across the Asia-Pacific markets were identified that are not purely outcomes-based or risk-sharing, but cover innovative high-cost medicines, areas of high unmet need, areas affecting small patient populations, and medicines where the evidence is uncertain. Key factors for consideration are the public environment and the general acceptance of such agreements; the level of available resources that impact the health care priorities in each market and the public demand for access to medicines and to innovation. The ability to undertake such agreements appears to depend significantly on the degree of centralized decision-making and the dominance of a "single payer" for negotiation; the ability to manage data - both to undertake health technology assessments and to have systems/infrastructure to collect data and demonstrate outcomes; the nature of local health care structures and the capabilities to implement schemes where the financing is linked to outcomes. Caution was shared across markets with a trend to "watch and wait" while evidence emerges elsewhere.

Original languageEnglish
JournalHealth Outcomes Research in Medicine
Volume3
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Aptitude
Delivery of Health Care
Health Priorities
Biomedical Technology Assessment
Negotiating
Decision Making
Costs and Cost Analysis
Population

Keywords

  • Access to health care
  • Asia
  • Asia Pac
  • Asia Pacific
  • Asia-Pac
  • Asia-Pacific
  • Conditional coverage
  • Conditional evidence development
  • Conditional treatment continuation
  • Coverage with evidence development
  • Differential pricing
  • Finance-based schemes
  • Health technology assessment
  • Innovative pricing
  • Managed entry
  • Outcomes guarantee
  • Outcomes-based
  • Outcomes-based scheme
  • Patient access
  • Performance-based
  • Price
  • Reimbursement
  • Risk-sharing
  • Southeast Asia
  • Value-based pricing

ASJC Scopus subject areas

  • Health Policy

Cite this

Coulton, L., Annemans, L., Carter, R., Herrera, M. B., Thabrany, H., Lim, J., ... Keskinaslan, A. (2012). Outcomes-based risk-sharing schemes: Is there a potential role in the Asia-Pacific markets? Health Outcomes Research in Medicine, 3(4). https://doi.org/10.1016/j.ehrm.2012.07.002

Outcomes-based risk-sharing schemes : Is there a potential role in the Asia-Pacific markets? / Coulton, Lisbet; Annemans, Lieven; Carter, Rob; Herrera, Maya Baltazar; Thabrany, Hasbullah; Lim, Jeremy; Lee, Kenneth K.C.; Chen, Wen; Chaiyakunapruk, Nathorn; Chern, Herng Der; Lee, Tae Jin; Nakamura, Hiroshi; Tarn, Tony Yen Huei; Keskinaslan, Abdulkadir.

In: Health Outcomes Research in Medicine, Vol. 3, No. 4, 2012.

Research output: Contribution to journalArticle

Coulton, L, Annemans, L, Carter, R, Herrera, MB, Thabrany, H, Lim, J, Lee, KKC, Chen, W, Chaiyakunapruk, N, Chern, HD, Lee, TJ, Nakamura, H, Tarn, TYH & Keskinaslan, A 2012, 'Outcomes-based risk-sharing schemes: Is there a potential role in the Asia-Pacific markets?', Health Outcomes Research in Medicine, vol. 3, no. 4. https://doi.org/10.1016/j.ehrm.2012.07.002
Coulton, Lisbet ; Annemans, Lieven ; Carter, Rob ; Herrera, Maya Baltazar ; Thabrany, Hasbullah ; Lim, Jeremy ; Lee, Kenneth K.C. ; Chen, Wen ; Chaiyakunapruk, Nathorn ; Chern, Herng Der ; Lee, Tae Jin ; Nakamura, Hiroshi ; Tarn, Tony Yen Huei ; Keskinaslan, Abdulkadir. / Outcomes-based risk-sharing schemes : Is there a potential role in the Asia-Pacific markets?. In: Health Outcomes Research in Medicine. 2012 ; Vol. 3, No. 4.
@article{45575c3c09854f76b72755b2d9ef01b3,
title = "Outcomes-based risk-sharing schemes: Is there a potential role in the Asia-Pacific markets?",
abstract = "OBJECTIVES: To provide a commentary on outcomes-based risk-sharing schemes in Europe and the US, and to assess characteristics of such schemes and whether they have a potential role in the Asia-Pacific markets. This commentary also examines current experience in the Asia-Pacific markets and considers criteria for such agreements as they might relate to the different health care environments. SUMMARY: Future opportunities for patient access schemes, and specifically, a role for outcomesbased risk-sharing schemes, exist in the Asia-Pacific markets. Four types of agreements across the Asia-Pacific markets were identified that are not purely outcomes-based or risk-sharing, but cover innovative high-cost medicines, areas of high unmet need, areas affecting small patient populations, and medicines where the evidence is uncertain. Key factors for consideration are the public environment and the general acceptance of such agreements; the level of available resources that impact the health care priorities in each market and the public demand for access to medicines and to innovation. The ability to undertake such agreements appears to depend significantly on the degree of centralized decision-making and the dominance of a {"}single payer{"} for negotiation; the ability to manage data - both to undertake health technology assessments and to have systems/infrastructure to collect data and demonstrate outcomes; the nature of local health care structures and the capabilities to implement schemes where the financing is linked to outcomes. Caution was shared across markets with a trend to {"}watch and wait{"} while evidence emerges elsewhere.",
keywords = "Access to health care, Asia, Asia Pac, Asia Pacific, Asia-Pac, Asia-Pacific, Conditional coverage, Conditional evidence development, Conditional treatment continuation, Coverage with evidence development, Differential pricing, Finance-based schemes, Health technology assessment, Innovative pricing, Managed entry, Outcomes guarantee, Outcomes-based, Outcomes-based scheme, Patient access, Performance-based, Price, Reimbursement, Risk-sharing, Southeast Asia, Value-based pricing",
author = "Lisbet Coulton and Lieven Annemans and Rob Carter and Herrera, {Maya Baltazar} and Hasbullah Thabrany and Jeremy Lim and Lee, {Kenneth K.C.} and Wen Chen and Nathorn Chaiyakunapruk and Chern, {Herng Der} and Lee, {Tae Jin} and Hiroshi Nakamura and Tarn, {Tony Yen Huei} and Abdulkadir Keskinaslan",
year = "2012",
doi = "10.1016/j.ehrm.2012.07.002",
language = "English",
volume = "3",
journal = "Health Outcomes Research in Medicine",
issn = "1877-1319",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Outcomes-based risk-sharing schemes

T2 - Is there a potential role in the Asia-Pacific markets?

AU - Coulton, Lisbet

AU - Annemans, Lieven

AU - Carter, Rob

AU - Herrera, Maya Baltazar

AU - Thabrany, Hasbullah

AU - Lim, Jeremy

AU - Lee, Kenneth K.C.

AU - Chen, Wen

AU - Chaiyakunapruk, Nathorn

AU - Chern, Herng Der

AU - Lee, Tae Jin

AU - Nakamura, Hiroshi

AU - Tarn, Tony Yen Huei

AU - Keskinaslan, Abdulkadir

PY - 2012

Y1 - 2012

N2 - OBJECTIVES: To provide a commentary on outcomes-based risk-sharing schemes in Europe and the US, and to assess characteristics of such schemes and whether they have a potential role in the Asia-Pacific markets. This commentary also examines current experience in the Asia-Pacific markets and considers criteria for such agreements as they might relate to the different health care environments. SUMMARY: Future opportunities for patient access schemes, and specifically, a role for outcomesbased risk-sharing schemes, exist in the Asia-Pacific markets. Four types of agreements across the Asia-Pacific markets were identified that are not purely outcomes-based or risk-sharing, but cover innovative high-cost medicines, areas of high unmet need, areas affecting small patient populations, and medicines where the evidence is uncertain. Key factors for consideration are the public environment and the general acceptance of such agreements; the level of available resources that impact the health care priorities in each market and the public demand for access to medicines and to innovation. The ability to undertake such agreements appears to depend significantly on the degree of centralized decision-making and the dominance of a "single payer" for negotiation; the ability to manage data - both to undertake health technology assessments and to have systems/infrastructure to collect data and demonstrate outcomes; the nature of local health care structures and the capabilities to implement schemes where the financing is linked to outcomes. Caution was shared across markets with a trend to "watch and wait" while evidence emerges elsewhere.

AB - OBJECTIVES: To provide a commentary on outcomes-based risk-sharing schemes in Europe and the US, and to assess characteristics of such schemes and whether they have a potential role in the Asia-Pacific markets. This commentary also examines current experience in the Asia-Pacific markets and considers criteria for such agreements as they might relate to the different health care environments. SUMMARY: Future opportunities for patient access schemes, and specifically, a role for outcomesbased risk-sharing schemes, exist in the Asia-Pacific markets. Four types of agreements across the Asia-Pacific markets were identified that are not purely outcomes-based or risk-sharing, but cover innovative high-cost medicines, areas of high unmet need, areas affecting small patient populations, and medicines where the evidence is uncertain. Key factors for consideration are the public environment and the general acceptance of such agreements; the level of available resources that impact the health care priorities in each market and the public demand for access to medicines and to innovation. The ability to undertake such agreements appears to depend significantly on the degree of centralized decision-making and the dominance of a "single payer" for negotiation; the ability to manage data - both to undertake health technology assessments and to have systems/infrastructure to collect data and demonstrate outcomes; the nature of local health care structures and the capabilities to implement schemes where the financing is linked to outcomes. Caution was shared across markets with a trend to "watch and wait" while evidence emerges elsewhere.

KW - Access to health care

KW - Asia

KW - Asia Pac

KW - Asia Pacific

KW - Asia-Pac

KW - Asia-Pacific

KW - Conditional coverage

KW - Conditional evidence development

KW - Conditional treatment continuation

KW - Coverage with evidence development

KW - Differential pricing

KW - Finance-based schemes

KW - Health technology assessment

KW - Innovative pricing

KW - Managed entry

KW - Outcomes guarantee

KW - Outcomes-based

KW - Outcomes-based scheme

KW - Patient access

KW - Performance-based

KW - Price

KW - Reimbursement

KW - Risk-sharing

KW - Southeast Asia

KW - Value-based pricing

UR - http://www.scopus.com/inward/record.url?scp=85027930985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027930985&partnerID=8YFLogxK

U2 - 10.1016/j.ehrm.2012.07.002

DO - 10.1016/j.ehrm.2012.07.002

M3 - Article

AN - SCOPUS:85027930985

VL - 3

JO - Health Outcomes Research in Medicine

JF - Health Outcomes Research in Medicine

SN - 1877-1319

IS - 4

ER -